[Medical treatment of renal cell carcinoma]. / Les médicaments du cancer du rein.
Prog Urol
; 23(15): 1225-37, 2013 Nov.
Article
in Fr
| MEDLINE
| ID: mdl-24183081
ABSTRACT
AIM:
To describe drugs used in renal cell carcinoma.METHOD:
Pubmed search for efficacy, mode of action and side effects for each molecule. Additional data were searched from the French regulatory agencies websites (HAS and ANSM).RESULTS:
Since 2007, a total of three different therapeutic classes in the management of metastatic renal cell carcinoma are available. These three classes are tyrosine kinase inhibitors with sunitinib and sorafenib, the anti-VEGF antibodies (bevacizumab which is associated with alpha interferon in the treatment of advanced kidney cancer) and mTOR inhibitors with temsirolimus and everolimus. These targeted therapies are a major progress in the treatment of patients with metastatic kidney cancer. The side effects encountered with these molecules are numerous but serious side effects are less than 5% of all reported side effects.CONCLUSIONS:
A better understanding of molecular mechanisms has enabled the development of new therapies for the treatment of metastatic renal cell carcinoma. In the future, a personalized approach taking into account the biology of each tumor could be created to provide a more targeted treatment.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Renal Cell
/
Kidney Neoplasms
/
Antineoplastic Agents
Language:
Fr
Journal:
Prog Urol
Year:
2013
Document type:
Article